CN103687942A - 病毒样颗粒及其制备方法 - Google Patents

病毒样颗粒及其制备方法 Download PDF

Info

Publication number
CN103687942A
CN103687942A CN201280022947.1A CN201280022947A CN103687942A CN 103687942 A CN103687942 A CN 103687942A CN 201280022947 A CN201280022947 A CN 201280022947A CN 103687942 A CN103687942 A CN 103687942A
Authority
CN
China
Prior art keywords
papmv
vlp
ssrna
approximately
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280022947.1A
Other languages
English (en)
Chinese (zh)
Inventor
德尼·勒克莱尔
皮埃尔·萨瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Folia Biotech Inc
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Publication of CN103687942A publication Critical patent/CN103687942A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/26042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201280022947.1A 2011-05-13 2012-05-01 病毒样颗粒及其制备方法 Pending CN103687942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485955P 2011-05-13 2011-05-13
US61/485,955 2011-05-13
PCT/CA2012/050279 WO2012155262A1 (en) 2011-05-13 2012-05-01 Virus-like particles and process for preparing same

Publications (1)

Publication Number Publication Date
CN103687942A true CN103687942A (zh) 2014-03-26

Family

ID=47176093

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280023824.XA Pending CN103648528A (zh) 2011-05-13 2012-05-01 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途
CN201280022947.1A Pending CN103687942A (zh) 2011-05-13 2012-05-01 病毒样颗粒及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201280023824.XA Pending CN103648528A (zh) 2011-05-13 2012-05-01 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途

Country Status (11)

Country Link
US (2) US9833504B2 (enExample)
EP (2) EP2707027A4 (enExample)
JP (2) JP6213461B2 (enExample)
CN (2) CN103648528A (enExample)
AU (1) AU2012255595A1 (enExample)
BR (2) BR112013029143A2 (enExample)
CA (2) CA2835967A1 (enExample)
DK (1) DK2707480T3 (enExample)
MX (1) MX2013013228A (enExample)
NO (1) NO2800866T3 (enExample)
WO (2) WO2012155262A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110785176A (zh) * 2017-06-01 2020-02-11 利兹大学 病毒样颗粒

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648528A (zh) 2011-05-13 2014-03-19 弗利亚生物技术公司 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途
CA2924819A1 (en) * 2013-09-19 2015-03-26 Folia Biotech Inc. Papaya mosaic virus and virus-like particles in cancer therapy
US10098936B2 (en) 2014-04-02 2018-10-16 Case Western Reserve University Vaccination using plant virus particles linked to HER2 antigens
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
JP2017528137A (ja) * 2014-09-11 2017-09-28 カディラ ヘルスケア リミティド 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
WO2016127262A1 (en) * 2015-02-12 2016-08-18 Folia Biotech Inc. Multimerized orthomyxovirus nucleoprotein and uses thereof
MX385484B (es) * 2017-06-28 2025-03-14 Univ Mexico Nac Autonoma Vlps derivadas de virus de planta con dsrna encapsidado y metodo de sintesis.
FR3106648B1 (fr) * 2020-01-28 2022-05-27 Arkema France Structure multicouche pour le transport ou le stockage de l’hydrogene

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058396A1 (en) * 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
WO2004004761A2 (en) 2002-07-05 2004-01-15 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
KR20060031607A (ko) 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 패킹된 바이러스-양 입자
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
WO2008058369A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
US7799281B2 (en) 2007-01-16 2010-09-21 Festo Corporation Flux concentrator for biomagnetic particle transfer device
EP2082042A4 (en) 2007-01-26 2010-08-18 Folia Biotech Inc VACCINE VACCINE FROM PAPAYA MOSAIC AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS
CA2742288A1 (en) 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2010030790A2 (en) 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
CN103648528A (zh) 2011-05-13 2014-03-19 弗利亚生物技术公司 番木瓜花叶病毒组合物及其用于刺激先天免疫应答的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058396A1 (en) * 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIEBOLD,S.S, ET AL: "Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA", 《SCIENCE》 *
ERICKSON,J.W, ET AL: "the self-assembly of papaya mosaic virus", 《VIROLOGY》 *
TREMBLAY,M.H, ET AL: "Effect of mutations K97A and E128A on RNA binding and self-assembly of papaya mosaic potexvirus coat protain", 《FEBS J》 *
曲静: "一个马铃薯X病毒分离物的外壳蛋白基因序列分析和株系鉴定", 《中国优秀硕士学位论文集》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110785176A (zh) * 2017-06-01 2020-02-11 利兹大学 病毒样颗粒
US12209241B2 (en) 2017-06-01 2025-01-28 The University Of Leeds Virus like particle

Also Published As

Publication number Publication date
EP2707027A4 (en) 2015-06-03
JP6213461B2 (ja) 2017-10-18
CN103648528A (zh) 2014-03-19
WO2012155262A1 (en) 2012-11-22
JP6093926B2 (ja) 2017-03-15
BR112013029143A2 (pt) 2017-07-11
US20140154288A1 (en) 2014-06-05
CA2835972A1 (en) 2012-11-22
US20140255439A1 (en) 2014-09-11
MX2013013228A (es) 2013-12-12
JP2014514350A (ja) 2014-06-19
AU2012255595A1 (en) 2013-12-12
EP2707480B1 (en) 2017-08-02
BR112013029144A2 (pt) 2017-07-11
EP2707480A1 (en) 2014-03-19
CA2835967A1 (en) 2012-11-22
NO2800866T3 (enExample) 2018-04-14
EP2707027A1 (en) 2014-03-19
JP2014519817A (ja) 2014-08-21
DK2707480T3 (da) 2017-11-13
US9833504B2 (en) 2017-12-05
EP2707480A4 (en) 2015-01-07
WO2012155261A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
CN103687942A (zh) 病毒样颗粒及其制备方法
JP4235359B2 (ja) Ｌｔｂアジュバントを含むワクチン
CN105899217A (zh) 癌症疗法中的番木瓜花叶病毒和病毒样颗粒
CN114634578B (zh) 针对新型冠状病毒感染的疫苗组合物
JP2018502166A (ja) 口蹄疫ワクチン
JP2010538619A (ja) Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用
Wong et al. COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai.
Ren et al. Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections
JP5735121B2 (ja) インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン
US20250186575A1 (en) Vaccine construct and uses thereof
EP4026558A1 (en) Composite protein monomer having non-structural protein of virus supported thereon, aggregate of composite protein monomer, and component vaccine comprising aggregate as active ingredient
KR101366702B1 (ko) 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법
KR20240011134A (ko) Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법
KR102211077B1 (ko) 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
TWI412588B (zh) 重組病毒蛋白及顆粒
WO2022085648A1 (ja) 融合タンパク質及びワクチン
US20180250602A1 (en) Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
CN114632148A (zh) 病原样抗原疫苗及其制备方法
KR102102065B1 (ko) 호흡기 세포융합 바이러스 백신
AU2012255594A1 (en) Papaya Mosaic Virus compositions and uses thereof for stimulation of the innate immune response
WO2022149609A1 (ja) Ｍｈｃ分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法
WO2016127262A1 (en) Multimerized orthomyxovirus nucleoprotein and uses thereof
CN118695869A (zh) 泛-肺病毒疫苗组合物及其使用方法
JPH03130082A (ja) ワクチン用ポリペプチド
US20220193225A1 (en) Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326